Cargando…

COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies

BACKGROUND: Disease-modifying therapies (DMTs) for multiple sclerosis (MS) target immunity and have the potential to increase the risk of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and alter its clinical course. We assessed these risks in patients with MS (PwMS). OBJECTIV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reder, Anthony T., Centonze, Diego, Naylor, Maria L., Nagpal, Anjali, Rajbhandari, Rajani, Altincatal, Arman, Kim, Michelle, Berdofe, Aaron, Radhakrishnan, Maha, Jung, Eunice, Sandrock, Alfred W., Smirnakis, Karen, Popescu, Catrinel, de Moor, Carl
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7980129/ https://www.ncbi.nlm.nih.gov/pubmed/33743151 http://dx.doi.org/10.1007/s40263-021-00804-1

Ejemplares similares

Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics
por: Hersh, Carrie M, et al.
Publicado: (2022)

Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring
por: Calabresi, Peter A, et al.
Publicado: (2020)

Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate
por: Scott, Thomas F., et al.
Publicado: (2021)

Measuring treatment response to advance precision medicine for multiple sclerosis
por: Calabresi, Peter A., et al.
Publicado: (2021)

Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening
por: Phillips, Glenn A, et al.
Publicado: (2014)

Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry
por: Hellwig, Kerstin, et al.
Publicado: (2020)

Pivotal Trials in Multiple Sclerosis: Similarities Prove Not to Be Useful
por: Avolio, Carlo, et al.
Publicado: (2021)

Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis Episode
por: Plavina, Tatiana, et al.
Publicado: (2020)

Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients’ Health State Utility
por: Lawson, Richard, et al.
Publicado: (2016)

Clostridium epsilon toxin is excessive in multiple sclerosis and provokes multifocal lesions in mouse models
por: Reder, Anthony T.
Publicado: (2023)

Theoretical and Therapeutic Implications of the Spasticity-Plus Syndrome Model in Multiple Sclerosis
por: Bruno, Antonio, et al.
Publicado: (2022)

T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy
por: Reder, Anthony T, et al.
Publicado: (2022)

Vitamin D and Multiple Sclerosis: A Comprehensive Review
por: Sintzel, Martina B., et al.
Publicado: (2017)

Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis
por: Chang, Ih, et al.
Publicado: (2022)

Associations Between Timeliness of Therapy and Clinical and Economic Outcomes Among Patients With Serious Infections Due to Gram-negative Bacteria (GNB): How Much Does Delayed Appropriate Therapy (DAT) Matter?
por: Bonine, Nicole G, et al.
Publicado: (2017)

Carbapenem-resistant Enterobacteriaceae (CRE) or Delayed Appropriate Therapy (DAT)—Does One Affect Outcomes More Than the Other Among Patients With Serious Infections Due to Enterobacteriaceae?
por: Lodise, Thomas, et al.
Publicado: (2017)

Treatment sequences for advanced renal cell carcinoma: A health economic assessment
por: Deniz, Baris, et al.
Publicado: (2019)

The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis
por: Burkill, Sarah, et al.
Publicado: (2019)

The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis
por: Hunter, Samuel F., et al.
Publicado: (2015)

Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps
por: Guo, Shien, et al.
Publicado: (2012)

Antimicrobial Resistance or Delayed Appropriate Therapy—Does One Influence Outcomes More Than the Other Among Patients With Serious Infections Due to Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacteriaceae?
por: Lodise, Thomas P, et al.
Publicado: (2019)

Inflammation and Corticospinal Functioning in Multiple Sclerosis: A TMS Perspective
por: Stampanoni Bassi, Mario, et al.
Publicado: (2020)

Macrophage Plasticity and Polarization Are Altered in the Experimental Model of Multiple Sclerosis
por: Leuti, Alessandro, et al.
Publicado: (2021)

Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate
por: Lyons, Jennifer, et al.
Publicado: (2022)

Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
por: Centonze, Diego, et al.
Publicado: (2021)

Dementia Coding, Workup, and Treatment in the VA New England Healthcare System
por: Cho, Kelly, et al.
Publicado: (2014)

Application of dynamic modeling for survival estimation in advanced renal cell carcinoma
por: Deniz, Baris, et al.
Publicado: (2018)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Exploring the role of microglia in mood disorders associated with experimental multiple sclerosis
por: Gentile, Antonietta, et al.
Publicado: (2015)

Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
por: Filippi, Massimo, et al.
Publicado: (2022)

Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164–76. doi:10.1007/s12325-019-00923-8
por: Sandrock, Alfred W., et al.
Publicado: (2019)

Modified Exfoliated Carbon Nanoplatelets as Sorbents for Ammonium from Natural Mineral Waters
por: Ion, Ion, et al.
Publicado: (2021)

Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
por: Filippi, Massimo, et al.
Publicado: (2022)

Morphological Outer Retina Findings in Multiple Sclerosis Patients With or Without Optic Neuritis
por: Ziccardi, Lucia, et al.
Publicado: (2020)

Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial
por: Cutter, Gary, et al.
Publicado: (2023)

Disability and Fatigue Can Be Objectively Measured in Multiple Sclerosis
por: Motta, Caterina, et al.
Publicado: (2016)

Predictors of Evolution Into Multiple Sclerosis After a First Acute Demyelinating Syndrome in Children and Adolescents
por: Papetti, Laura, et al.
Publicado: (2019)

Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study
por: D’Amico, Emanuele, et al.
Publicado: (2023)

Optimizing the “Time to pregnancy” in women with multiple sclerosis: the OPTIMUS Delphi survey
por: Carbone, Luigi, et al.
Publicado: (2023)

Immunomodulatory Effects of Exercise in Experimental Multiple Sclerosis
por: Gentile, Antonietta, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ik79u8ca1nrqa30khvqleofc8u